These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 38519055)
1. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Brouwer-Visser J; Fiaschi N; Deering RP; Cygan KJ; Scott D; Jeong S; Boucher L; Gupta NT; Gupta S; Adler C; Topp MS; Bannerji R; Duell J; Advani RH; Flink DM; Chaudhry A; Thurston G; Ambati SR; Jankovic V J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519055 [TBL] [Abstract][Full Text] [Related]
2. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963 [TBL] [Abstract][Full Text] [Related]
3. CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models. Wei J; Montalvo-Ortiz W; Yu L; Krasco A; Olson K; Rizvi S; Fiaschi N; Coetzee S; Wang F; Ullman E; Ahmed HS; Herlihy E; Lee K; Havel L; Potocky T; Ebstein S; Frleta D; Khatri A; Godin S; Hamon S; Brouwer-Visser J; Gorenc T; MacDonald D; Hermann A; Chaudhry A; Sirulnik A; Olson W; Lin J; Thurston G; Lowy I; Murphy AJ; Smith E; Jankovic V; Sleeman MA; Skokos D Sci Transl Med; 2022 Nov; 14(670):eabn1082. PubMed ID: 36350988 [TBL] [Abstract][Full Text] [Related]
4. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. Zhu M; Olson K; Kirshner JR; Khaksar Toroghi M; Yan H; Haber L; Meagher C; Flink DM; Ambati SR; Davis JD; DiCioccio AT; Smith EJ; Retter MW Clin Transl Sci; 2022 Apr; 15(4):954-966. PubMed ID: 34997701 [TBL] [Abstract][Full Text] [Related]
5. Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy. Irvin SC; D'Orvilliers A; Bloch N; Boccio K; Pennucci J; Brouwer-Visser J; Ullman E; Rajadhyaksha M; Hassanein M; Potocky T; Torri A; Hermann A; Partridge MA AAPS J; 2022 Jun; 24(4):76. PubMed ID: 35725847 [TBL] [Abstract][Full Text] [Related]
6. Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy. Weinstock M; Elavalakanar P; Bright S; Ambati SR; Brouwer-Visser J; Pourpe S; Fiaschi N; Jankovic V; Thurston G; Deering RP; Chaudhry A; Joyce R; Arnason J Br J Haematol; 2022 Nov; 199(3):366-370. PubMed ID: 35892294 [TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Kim TM; Taszner M; Novelli S; Cho SG; Villasboas JC; Merli M; Jiménez-Ubieto A; Tessoulin B; Poon LM; Tucker D; Walewski J; Yi S; Song Y; Chong G; Bachy E; Guidez S; Alonso A; Jagadeesh D; Zhang W; Magnano L; Iskierka-Jażdżewska E; Tani M; Shen B; Uppala A; Zhu M; Shariff S; Brouwer-Visser J; Chaudhry A; Mohamed H; Ambati S; Luminari S; Ann Oncol; 2024 Aug; ():. PubMed ID: 39147364 [TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Bock AM; Nowakowski GS; Wang Y Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296 [TBL] [Abstract][Full Text] [Related]
10. The value of bispecific antibodies in relapsed and refractory DLBCL. Lewis KL; Cheah CY Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535 [TBL] [Abstract][Full Text] [Related]
11. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model. Cremasco F; Menietti E; Speziale D; Sam J; Sammicheli S; Richard M; Varol A; Klein C; Umana P; Bacac M; Colombetti S; Perro M PLoS One; 2021; 16(1):e0241091. PubMed ID: 33406104 [TBL] [Abstract][Full Text] [Related]
12. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582 [TBL] [Abstract][Full Text] [Related]
13. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202 [TBL] [Abstract][Full Text] [Related]
14. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Nuvvula S; Dahiya S; Patel SA Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844 [TBL] [Abstract][Full Text] [Related]
15. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. Schuster SJ; Huw LY; Bolen CR; Maximov V; Polson AG; Hatzi K; Lasater EA; Assouline SE; Bartlett NL; Budde LE; Matasar MJ; Koeppen H; Piccione EC; Wilson D; Wei MC; Yin S; Penuel E Blood; 2024 Feb; 143(9):822-832. PubMed ID: 38048694 [TBL] [Abstract][Full Text] [Related]
16. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857 [TBL] [Abstract][Full Text] [Related]
17. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. Zinzani PL; Minotti G J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Bröske AE; Korfi K; Belousov A; Wilson S; Ooi CH; Bolen CR; Canamero M; Alcaide EG; James I; Piccione EC; Carlile DJ; Dimier N; Umaña P; Bacac M; Weisser M; Dickinson M Blood Adv; 2022 Feb; 6(3):1025-1037. PubMed ID: 34941996 [TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Matsuki E; Younes A Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488 [TBL] [Abstract][Full Text] [Related]
20. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. Izutsu K; Kumode T; Yuda J; Nagai H; Mishima Y; Suehiro Y; Yamamoto K; Fujisaki T; Ishitsuka K; Ishizawa K; Ikezoe T; Nishikori M; Akahane D; Fujita J; Dinh M; Soong D; Noguchi H; Buchbjerg JK; Favaro E; Fukuhara N Cancer Sci; 2023 Dec; 114(12):4643-4653. PubMed ID: 37921363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]